Itoh Shinji, Maeda Takashi, Shimada Mitsuo, Aishima Shin-ichi, Shirabe Ken, Tanaka Shinji, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Clin Cancer Res. 2004 Apr 15;10(8):2812-7. doi: 10.1158/1078-0432.ccr-1046-03.
Although hepatocellular carcinoma (HCC) is the most common cancer of the human liver, the mechanisms that regulate HCC development and progression remain unclear. The aim of this study was to investigate whether focal adhesion kinase (FAK) is involved in the progression of human HCC.
Western blot analysis for FAK was performed on three HCC cell lines. We reviewed 64 consecutive patients who had undergone initial liver resection for HCC without preoperative treatment. Immunohistochemistry analysis for FAK was performed on paraffin-embedded tissues. FAK expression was confirmed by Western blot analysis in several clinical samples. We investigated the correlation between FAK expression and clinical outcome.
FAK proteins were detected in all HCC cell lines. Hepatocytes in the normal liver and chronic hepatitis with or without cirrhosis were negative for immunohistochemical staining for FAK expression. Cytoplasmic FAK expression was observed in 18 of 64 patients (28.1%), and this positive staining was correlated with gender (P < 0.05), a lower level of serum albumin (P < 0.05), and portal venous invasion (P < 0.01). Positive staining for FAK was associated with significantly poorer survival (P < 0.05). In multivariate analysis, FAK overexpression was an independent factor in determining the prognosis of patients.
These data suggest that FAK plays an important role in promoting tumor progression, especially vascular invasion, in HCC. FAK could play an important role in HCC progression and would be a novel target for HCC therapeutics as well as a prognostic marker.
尽管肝细胞癌(HCC)是人类肝脏最常见的癌症,但调节HCC发生和进展的机制仍不清楚。本研究的目的是调查粘着斑激酶(FAK)是否参与人类HCC的进展。
对三种HCC细胞系进行FAK的蛋白质印迹分析。我们回顾了64例未经术前治疗而接受初次肝脏切除术治疗HCC的连续患者。对石蜡包埋组织进行FAK的免疫组织化学分析。通过蛋白质印迹分析在多个临床样本中证实了FAK表达。我们研究了FAK表达与临床结果之间的相关性。
在所有HCC细胞系中均检测到FAK蛋白。正常肝脏以及伴有或不伴有肝硬化的慢性肝炎中的肝细胞,其FAK表达的免疫组织化学染色均为阴性。64例患者中有18例(28.1%)观察到细胞质FAK表达,这种阳性染色与性别(P<0.05)、较低的血清白蛋白水平(P<0.05)和门静脉侵犯(P<0.01)相关。FAK阳性染色与显著较差的生存率相关(P<0.05)。在多变量分析中,FAK过表达是决定患者预后的独立因素。
这些数据表明,FAK在促进HCC的肿瘤进展尤其是血管侵犯中起重要作用。FAK可能在HCC进展中起重要作用,并且将成为HCC治疗的新靶点以及预后标志物。